While encouraged that such results might translate to improved ambulation and respiratory function in DMD patients, we realized that further development of an NF-κB inhibitor would require investigation into its effects on dystrophic cardiac muscle. The gene discussed is NFKB1; the disease is Duchenne muscular dystrophy.